Close Menu

NEW YORK – Fluidigm said on Wednesday that it will exclusively distribute antibodies from Bethyl Laboratories for use with Fluidigm's Imaging Mass Cytometry technology.

Bethyl Laboratories has a portfolio of more than 9,500 primary and secondary antibodies, including the recombinant monoclonal antibodies that are well-suited for imaging studies. Under the new agreement, antibody products manufactured by Bethyl will be verified on Fluidigm's Hyperion imaging system and subsequently offered to Fluidigm's customers.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

According to the Wall Street Journal, the Food and Drug Administration may soon issue an Emergency Use Authorization for convalescent plasma to treat COVID-19 patients.

Minnesota police have used genetic genealogy to make an arrest in a 1986 cold case, reports NBC News.

Researchers have used CRISPR-Cas9 to efficiently target a cephalopod pigmentation gene, as they report in Current Biology.

In Science this week: chromatin accessibility of microglia during fetal development, and more.

Sep
09
Sponsored by
10x Genomics

Recent advances in spatially resolved transcriptomics have greatly expanded the knowledge of complex multicellular biological systems.